Pregnant Women Who Took Pfizer’s RSV Vaccine Were More Likely to Give Birth Prematurely

A new peer-reviewed study published in BMJ Open confirms earlier concerns that Pfizer’s Abrysvo RSV vaccine increases the risk of preterm birth in pregnant women — findings initially seen in clinical trials but downplayed during FDA approval.

A study from the University of Ottawa, published in BMJ Open, found that pregnant women vaccinated with Pfizer’s Abrysvo RSV shot were more likely to deliver prematurely — often within days of receiving the vaccine. These findings reinforce concerns observed during earlier clinical trials, which the FDA acknowledged but proceeded to approve the vaccine in 2023 with post-marketing conditions. Notably, GSK halted a similar RSV vaccine trial due to similar safety signals. Critics argue Pfizer failed to fully inform trial participants of the risks, violating ethical standards.

Global health agencies remain inconsistent in their recommendations for RSV vaccination during pregnancy, prompting questions about regulatory reliability and public trust. Experts from Canada, the U.S., and the U.K. cited in the article warn that the risks are being downplayed, poorly communicated, and pose potential harm to vulnerable pregnant women.

Full article from CHD’s The Defender HERE